A health publication that pretends not to have conflicts is more dangerous than one that names them. This page names them.
Provider relationships
GLP Agonists earns no provider payment, referral fee, or sponsorship revenue from any provider. Provider relationships held as of July 23, 2026:
- NexLife — provider (no financial relationship); outbound links marked
rel="nofollow noopener".
No provider relationships exist that could influence rankings. The same five-pillar scoring methodology is applied to every reviewed program, partner or not. We will not raise a partner's score, lower a non-partner's score, hide a partner's weaknesses, or hide a non-partner's strengths.
Reviewer/provider overlap
Material conflict of interest, disclosed:
Dr. J. Adam, MD — one of our clinical reviewers — is also the Medical Director at NexLife, the program we ranked as 2026 Editor's Pick.
What this means in practice
Dr. J. Adam's editorial role at GLP Agonists is bounded by a firewall designed to prevent his clinical-review authority from spilling into ranking decisions:
- What Dr. J. Adam does review: Medication names, dosing accuracy, drug-class taxonomy, FDA status, mechanism of action, contraindication lists, drug-drug interactions, common side effects, compounding-standard references.
- What Dr. J. Adam does not review: Provider rankings, comparison conclusions, language describing NexLife relative to competitors, pricing-comparison content, methodology weighting, the five-pillar rubric itself.
- Independent verification: Clinical claims that specifically concern NexLife (pharmacy sourcing, compounding standards, prescribing protocols) are independently verified by Dr. John Berg, PharmD, who has no relationship with NexLife.
- Per-page disclosure: Every page that mentions NexLife favorably carries a "Fact-checked by Dr. J. Adam, MD" line that lets readers click through to his bio, which discloses his NexLife role.
Other contributor relationships
- Amanda Chen (Lead Editor) — no equity, advisory, or contracted relationship with any reviewed provider.
- Dr. John Berg, PharmD (Clinical Reviewer, Pharmacy) — no equity, advisory, or contracted relationship with any reviewed provider, including NexLife.
- Maria Torres (Contributing Editor, Pricing) — no equity, advisory, or contracted relationship with any reviewed provider.
Ownership & funding
GLP Agonists is an independent editorial publication. It is not owned, operated, or controlled by NexLife, by any other reviewed provider, by any pharmaceutical manufacturer, or by any health-insurance carrier. Revenue is from provider payment and editorial sponsorship of content categories (never of individual rankings).
What we do not accept
- Direct payment from any reviewed provider in exchange for a ranking position, a "best of" award, or favorable comparison language.
- Pharmaceutical-manufacturer payments for content concerning their products.
- Content drafted by a provider's marketing team and presented as editorial.
- "Provider responses" or "rebuttals" injected into reviews after publication outside the corrections process.
When conflicts change
If a contributor's relationships change — new equity stake, new advisory role, new contracted relationship with a reviewed provider — we update this page and add a corrections-log entry within 14 days. Readers who want to be notified of changes can email glpagonists@gmail.com with the subject line "COI WATCH".
Last reviewed July 23, 2026.